流感和流感大流行应对:我们如何能打赢这场防控战

王大燕1 朱闻斐1 陈永坤2 舒跃龙1,2

(1.中国疾病预防控制中心病毒病预防控制所国家流感中心世界卫生组织流感参比和研究合作中心, 北京 102206)
(2.中山大学公共卫生学院 (深圳) , 广州 510275)
【创新点】时值1918大流感一百年,在过去的一百年里,我们在流感疫苗、药物以及流行病学和病原学研究等方面取得了很大进步;只有不断强化监测能力,加快通用疫苗的研发,方可在流感大流行的应对中取得主动权。

【摘要】1918年西班牙流感是人类历史上最严重的一次流感大流行, 时值1918流感大流行一百年, 我们回顾历史, 展望未来。在过去的一百年里, 尽管我们在流感疫苗、药物以及流行病学和病原学研究等方面取得了很大进步, 但只有不断强化监测能力, 加快通用疫苗的研发, 方可在流感大流行的应对中取得主动权。

【关键词】 “西班牙流感”大流行; 流感监测; 通用疫苗; 流感病毒;

【基金资助】 科技部应急专项 (项目号:10600100000015001206) , 题目:H7N9疫情防控科技攻关应急专项 科技部应急专项 (项目号:10600100000015001206) , 题目:H7N9疫情防控科技攻关应急专项

Download this article

    References

    [1]Johnson N P, Mueller J.Updating the accounts:global mortality of the 1918-1920"Spanish"influenza pandemic[J].Bull Hist Med, 2002, 76 (1) :105-115.

    [2]Shope R E.Swine influenza III.Filtration experiments and etiology[J].J Exp Med, 1931, 54:373-385.

    [3]Shope R E.The effect of hemophilus influenzae suis vaccines on swine influenza[J].J Exp Med, 1937, 66 (2) :169-175.

    [4]Hayden F G.Antivirals for influenza:historical perspectives and lessons learned[J].Antiviral Res, 2006, 71 (2-3) :372-378.

    [5]Hay A J, Wolstenholme A J, Skehel J J, Smith M H.The molecular basis of the specific anti-influenza action of amantadine[J].EMBO J, 1985, 4 (11) :3021-3024.

    [6]Von Itzstein M, Wu W Y, Kok G B, Pegg M S, Dyason J C, Jin B, Van Phan T, Smythe M L, White H F, Oliver S W, Colman P M, Varghese J N, Ryan D M, Woods J M, Bethell R C, Hotham V J, Cameron J M, Penn C R.Rational design of potent sialidase-based inhibitors of influenza virus replication[J].Nature, 1993, 363 (6428) :418-423.

    [7]Yamashita M.Laninamivir and its prodrug, CS-8958:long-acting neuraminidase inhibitors for the treatment of influenza[J].Antivir Chem Chemother, 2010, 21 (2) :71-84.

    [8]Babu Y S, Chand P, Bantia S, Kotian P, Dehghani A, El-Kattan Y, Lin T H, Hutchison T L, Elliott A J, Parker C D, Ananth S L, Horn L L, Laver G W, Montgomery J A.BCX-1812 (RWJ-270201) :discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design[J].J Med Chem, 2000, 43 (19) :3482-3486.

    [9]Centers for Disease C, Prevention.Isolation of avian influenza A (H5N1) viruses from humans--Hong Kong, May-December 1997[J].MMWR Morb Mortal Wkly Rep, 1997, 46 (50) :1204-1207.

    [10]Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y.Human infection with a novel avian-origin influenza A (H7N9) virus[J].N Engl J Med, 2013, 368 (20) :1888-1897.

    [11]Hause B M, Ducatez M, Collin E A, Ran Z, Liu R, Sheng Z, Armien A, Kaplan B, Chakravarty S, Hoppe A D, Webby R J, Simonson R R, Li F.Isolation of a novel swine influenza virus from Oklahoma in 2011which is distantly related to human influenza C viruses[J/OL].PLoS Pathog, 2013, 9 (2) :e1003176.

    [12]Anonymous.Palese P, Shaw M L.Orthomyxoviridae:The viruses and their replication.In:Knipe DM, Howley PM, editors.Fields Virology, Fifth Edition.Philadelphia:Lippincott Williams&Wilkins[M].2007:1647-1690.

    [13]Fouchier R A, Munster V, Wallensten A, Bestebroer T M, Herfst S, Smith D, Rimmelzwaan G F, Olsen B, Osterhaus A D.Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls[J].J Virol, 2005, 79 (5) :2814-2822.

    [14]Webster R G, Bean W J, Gorman O T, Chambers T M, Kawaoka Y.Evolution and ecology of influenza A viruses[J].Microbiol Rev, 1992, 56 (1) :152-179.

    [15]Cheung T K, Poon L L.Biology of influenza a virus[J].Ann N Y Acad Sci, 2007, 1102:1-25.

    [16]Tong S, Li Y, Rivailler P, Conrardy C, Castillo D A, Chen L M, Recuenco S, Ellison J A, Davis C T, York I A, Turmelle A S, Moran D, Rogers S, Shi M, Tao Y, Weil M R, Tang K, Rowe L A, Sammons S, Xu X, Frace M, Lindblade K A, Cox N J, Anderson L J, Rupprecht C E, Donis R O.A distinct lineage of influenza A virus from bats[J].Proc Natl Acad Sci U S A, 2012, 109 (11) :4269-4274.

    [17]Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, Chen L M, Johnson A, Tao Y, Dreyfus C, Yu W, McBride R, Carney P J, Gilbert A T, Chang J, Guo Z, Davis C T, Paulson J C, Stevens J, Rupprecht C E, Holmes E C, Wilson I A, Donis R O.New world bats harbor diverse influenza A viruses[J/OL].PLoS Pathog, 2013, 9 (10) :e1003657.

    [18]Brown I H.The epidemiology and evolution of influenza viruses in pigs[J].Vet Microbiol, 2000, 74 (1-2) :29-46.

    [19]Alexander D J.Ecological aspects of influenza A viruses in animals and their relationship to human influenza:a review[J].J R Soc Med, 1982, 75 (10) :799-811.

    [20]Paules C, Subbarao K.Influenza[J].Lancet, 2017, 390 (10095) :697-708.

    [21]Paules C I, Sullivan S G, Subbarao K, Fauci A S.Chasing seasonal influenza-the need for a universal influenza vaccine[J].N Engl J Med, 2018, 378 (1) :7-9.

    [22]Hayden F G, Sugaya N, Hirotsu N, Lee N, de Jong M D, Hurt A C, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A, Baloxavir Marboxil Investigators G.Baloxavir marboxil for uncomplicated influenza in adults and adolescents[J].N Engl J Med, 2018, 379 (10) :913-923.

    [23]Delang L, Abdelnabi R, Neyts J.Favipiravir as a potential countermeasure against neglected and emerging RNA viruses[J].Antiviral Res, 2018, 153:85-94.

    [24]Deyde V, Garten R, Sheu T, Smith C, Myrick A, Barnes J, Xu X, Shaw M, Klimov A, Gubareva L.Genomic events underlying the changes in adamantane resistance among influenza A (H3N2) viruses during2006-2008[J].Influenza Other Respir Viruses, 2009, 3 (6) :297-314.

    [25]Ison M G.Antivirals and resistance:influenza virus[J].Curr Opin Virol, 2011, 1 (6) :563-573.

    [26]Ward P, Small I, Smith J, Suter P, Dutkowski R.Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic[J].J Antimicrob Chemother, 2005, 55Suppl 1:i5-i21.

    [27]Lackenby A, Besselaar T G, Daniels R S, Fry A, Gregory V, Gubareva L V, Huang W, Hurt A C, Leang S K, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017[J].Antiviral Res, 2018, 157:38-46.

    [28]Lindstrom S E, Cox N J, Klimov A.Genetic analysis of human H2N2and early H3N2influenza viruses, 1957-1972:evidence for genetic divergence and multiple reassortment events[J].Virology, 2004, 328 (1) :101-119.

    [29]Scholtissek C, Rohde W, Von Hoyningen V, Rott R.On the origin of the human influenza virus subtypes H2N2and H3N2[J].Virology, 1978, 87 (1) :13-20.

    [30]Smith G J, Vijaykrishna D, Bahl J, Lycett S J, Worobey M, Pybus O G, Ma S K, Cheung C L, Raghwani J, Bhatt S, Peiris J S, Guan Y, Rambaut A.Origins and evolutionary genomics of the 2009swine-origin H1N1influenza A epidemic[J].Nature, 2009, 459 (7250) :1122-1125.

    [31]Shaw A.New technologies for new influenza vaccines[J].Vaccine, 2012, 30 (33) :4927-4933.

    [32]Erbelding E J, Post D J, Stemmy E J, Roberts P C, Augustine A D, Ferguson S, Paules C I, Graham B S, Fauci A S.A universal influenza vaccine:the strategic plan for the national institute of allergy and infectious diseases[J].J Infect Dis, 2018, 218 (3) :347-354.

This Article

ISSN:1000-8721

CN: 11-1865/R

Vol 34, No. 06, Pages 789-792

November 2018

Downloads:1

Share
Article Outline

创新点

摘要

参考文献